The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy

There is a trend to reduced incidence of early post-vitrectomy hemorrhage in patients undergoing vitrectomy for complications of proliferative diabetic retinopathy that have been pre-treated with intravitreal bevacizumab 1 week prior to surgery.